Novartis STI 571 Leukemia Trials Heading Toward NDA Filing At End Of 2001
Executive Summary
Product registration trials for Novartis' STI 571 for chronic myelogenous leukemia began at the end of 1999, and an NDA filing for the product is planned within the next 18 months.
You may also be interested in...
Novartis Studies Glivec As First-Line Therapy For CML In Phase III Trials
Novartis' Abl-kinase inhibitor Glivec has moved into Phase III trials as first-line therapy for chronic myeloid leukemia.
Novartis Studies Glivec As First-Line Therapy For CML In Phase III Trials
Novartis' Abl-kinase inhibitor Glivec has moved into Phase III trials as first-line therapy for chronic myeloid leukemia.
Novartis Deal With Vertex, NYSE Listing Bolster U.S. Presence
Novartis has augmented its U.S. research profile with a long-term drug discovery deal with Cambridge, Mass.-based Vertex Pharmaceuticals.